Hematology Oncology · Year 2 · from Hematology Oncology

Case 2: Acute Promyelocytic Leukemia (APL)

Patient Presentation

Demographics: 34-year-old female

Chief Complaint: Heavy menstrual bleeding, nosebleeds, and bruising for 1 week

History of Present Illness: The patient noticed unusually heavy menstrual bleeding this cycle requiring pad changes every 1-2 hours. She has had multiple episodes of prolonged nosebleeds and spontaneous bruising. She reports fatigue and mild shortness of breath. She has no prior bleeding history. She developed a large hematoma on her thigh after minor trauma 3 days ago that is still expanding.

Physical Examination:

  • Vital signs: BP 105/62, HR 108, RR 20, Temp 37.6C
  • General: Pale, anxious woman with dried blood at nares
  • HEENT: Nasal packing in place, conjunctival pallor
  • Cardiac: Tachycardic, flow murmur
  • Lungs: Clear
  • Abdomen: Soft, no organomegaly
  • Skin: Extensive ecchymoses, expanding thigh hematoma
  • Neurologic: Normal (no signs of intracranial bleeding)

Workup and Results

Complete Blood Count:

  • WBC: 2,800/uL
  • Differential: 45% abnormal promyelocytes
  • Hemoglobin: 8.5 g/dL
  • Platelets: 32,000/uL

Coagulation Studies:

  • PT/INR: 16.5 sec / 1.4 (prolonged)
  • aPTT: 42 sec (prolonged)
  • Fibrinogen: 85 mg/dL (low; normal 200-400)
  • D-dimer: 12,500 ng/mL (markedly elevated)

Peripheral Blood Smear:

  • Hypergranular promyelocytes with abundant azurophilic granules
  • Multiple Auer rods in some cells (faggot cells)
  • Bilobed nuclei in some cells

Bone Marrow:

  • 75% abnormal promyelocytes
  • Flow cytometry: CD13+, CD33+, CD117+, HLA-DR negative, CD34 negative

FISH/RT-PCR:

  • PML-RARA fusion: POSITIVE (confirms t(15;17))

Clinical Image

Peripheral blood smear in acute promyelocytic leukemia showing hypergranular promyelocyte with bundled Auer rods (faggot cell), virtually pathognomonic for APL with t(15;17).

Diagnosis

Acute Promyelocytic Leukemia (APL) with DIC

Key features:

  • Hypergranular promyelocytes with faggot cells
  • HLA-DR negative, CD34 negative immunophenotype
  • PML-RARA fusion positive (defines APL)
  • DIC with low fibrinogen and elevated D-dimer
  • Low/normal WBC = standard risk APL

Treatment Plan

  1. IMMEDIATE (do not wait for genetic confirmation):
  • Start ATRA (all-trans retinoic acid) 45 mg/m2/day divided BID
  • Clinical suspicion of APL is sufficient to initiate ATRA
  1. DIC management (aggressive support):
  • Transfuse cryoprecipitate to maintain fibrinogen >150 mg/dL
  • Platelet transfusion to maintain >30,000-50,000/uL
  • FFP as needed for active bleeding
  1. Definitive therapy (once diagnosis confirmed):
  • ATRA + Arsenic trioxide (ATO) for standard-risk APL
  • Consider adding idarubicin if high-risk (WBC >10,000)
  1. Monitoring:
  • Daily CBC, coags, fibrinogen until DIC resolves
  • Watch for differentiation syndrome (fever, dyspnea, weight gain, pulmonary infiltrates)
  • If differentiation syndrome: Start dexamethasone 10 mg BID immediately
  1. Prognosis:
  • APL is the most curable adult AML subtype (>90% cure rate)
  • Early death from hemorrhage is main risk if not promptly treated

Teaching Points

  1. APL is a medical emergency - start ATRA on clinical suspicion before genetic confirmation
  2. DIC is characteristic of APL due to release of procoagulant substances from granules
  3. Maintain fibrinogen >150 mg/dL and platelets >30-50K until coagulopathy resolves
  4. ATRA + ATO combination achieves >90% cure without traditional chemotherapy in standard-risk APL
  5. Differentiation syndrome occurs when promyelocytes differentiate into neutrophils and release cytokines
  6. HLA-DR and CD34 negativity help distinguish APL from other AML subtypes
  7. Faggot cells (bundles of Auer rods) are virtually pathognomonic for APL

All cases for this lecture as Markdown